Tolerability of prolonged linezolid therapy in bone and joint infection: Protective effect of rifampicin on the occurrence of anaemia?

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 10, 2010, Pages 2224-2230

  Legout, Laurence ^a   Valette, Michel ^a   Dezeque, Hervé ^b   Nguyen, Sophie ^a   Lemaire, Xavier ^a   Loïez, Caroline ^b   Caillaux, Michèle ^a   Beltrand, Eric ^a   Dubreuil, Luc ^a   Yazdanpanah, Yazdan ^a   Migaud, Henri ^b   Senneville, Eric ^a  

^a Tourcoing Hospital   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Haematological toxicities; Osteomyelitis; Oxazolidinone

Indexed keywords

CLINDAMYCIN; FOSFOMYCIN; FUSIDIC ACID; HEMOGLOBIN; LINEZOLID; PRISTINAMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TEICOPLANIN; TETRACYCLINE;

ACTINOMYCES; ADULT; AGED; ANEMIA; ANTIBIOTIC THERAPY; ARTICLE; BLOOD TRANSFUSION; BONE INFECTION; CHRONIC KIDNEY FAILURE; CHRONIC OSTEOMYELITIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYANOCOBALAMIN DEFICIENCY; DIABETIC FOOT; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG WITHDRAWAL; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; FEMALE; GROUPS BY AGE; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFECTIOUS ARTHRITIS; IRON DEFICIENCY; LEUKOCYTE COUNT; LEUKOPENIA; LISTERIA MONOCYTOGENES; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PERIPHERAL NEUROPATHY; PROSTHESIS INFECTION; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; STAPHYLOCOCCUS AUREUS; STOMACH DISEASE; STREPTOCOCCUS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME;

ACETAMIDES; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTI-BACTERIAL AGENTS; ARTHRITIS, INFECTIOUS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; OSTEOARTHRITIS; OXAZOLIDINONES; RIFAMPIN; THROMBOCYTOPENIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 77957243712     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq281     Document Type: Article

References (49)

1. Abb J. In vitro activities of tigecycline, daptomycin, linezolid and quinupristin/dalfopristin against glycopeptide-resistant Enterococcus faecium. Int J Antimicrob Agents 2007; 29: 358-60.
2. Birmingham MC, Rayner CR, Meagher AK et al. Linezolid for the treatment of multidrug-resistant, Gram-positive infections: experience from a compassionate-use program. Clin Infect Dis 2003; 36: 159-68.
3. Diekema DI, Jones RN. Oxazolidinones: a review. Drugs 2000; 59: 7-16.
4. French G. Safety and tolerability of linezolid. J Antimicrob Chemother 2003; 51 Suppl 2: ii45-53.
5. Grohs P, Kitzis MD, Gutmann L. In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47: 418-20.
6. Livermore DM. Linezolid in vitro: mechanism and antibacterial spectrum. J Antimicrob Chemother 2003; 51 Suppl 2: ii9-16.
7. Rybak MJ, Hershberger E, Moldovan T et al. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob Agents Chemother 2000; 44: 1062-6.
8. Sweeney MT, Zurenko GE. In vitro activities of linezolid combined with other antimicrobial agents against staphylococci, enterococci, pneumococci, and selected gram-negative organisms. Antimicrob Agents Chemother 2003; 47:1902-6.
9. Bassetti M, Righi E, Di Biagio A et al. Role of linezolid in the treatment of orthopedic infections. Expert Rev Anti Infect Ther 2005; 3: 343-52.
10. Lovering AM, Zhang J, Bannister GC et al. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J Antimicrob Chemother 2002; 50:73-7.
11. Patel R, Piper KE, Rouse MS et al. Linezolid therapy of Staphylococcus aureus experimental osteomyelitis. Antimicrob Agents Chemother 2000; 44: 3438-40.
12. Rana B, Butcher I, Grigoris P et al. Linezolid penetration into osteo-articular tissues. J Antimicrob Chemother 2002; 50: 747-50.
13. Rao N, Hamilton CW. Efficacy and safety of linezolid for Gram-positive orthopedic infections: a prospective case series. Diagn Microbiol Infect Dis 2007; 59: 173-9.
14. Rao N, Ziran BH, Hall RA et al. Successful treatment of chronic bone and joint infections with oral linezolid. Clin Orthop Relat Res 2004; 67-71.
15. Rayner CR, Baddour LM, Birmingham MC et al. Linezolid in the treatment of osteomyelitis: results of compassionate use experience. Infection 2004; 32: 8-14.
16. Rouse MS, Steckelberg JM, Patel R. In vitro activity of ceftobiprole, daptomycin, linezolid, and vancomycin against methicillin-resistant staphylococci associated with endocarditis and bone and joint infection. Diagn Microbiol Infect Dis 2007; 58: 363-5.
17. Rubinstein E, Isturiz R, Standiford HC et al. Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies. Antimicrob Agents Chemother 2003; 47: 1824-31.
18. Senneville E, Legout L, Valette M et al. Effectiveness and tolerability of prolonged linezolid treatment for chronic osteomyelitis: a retrospective study. Clin Ther 2006; 28: 1155-63.
19. Soriano A, Gomez J, Gomez L et al. Efficacy and tolerability of prolonged linezolid therapy in the treatment of orthopedic implant infections. Eur J Clin Microbiol Infect Dis 2007; 26: 353-6.
20. Stalker DJ, Jungbluth GL, Hopkins NK et al. Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers. J Antimicrob Chemother 2003; 51: 1239-46.
21. Aneziokoro CO, Cannon JP, Pachucki CT et al. The effectiveness and safety of oral linezolid for the primary and secondary treatment of osteomyelitis. J Chemother 2005; 17: 643-50.
22. Bernstein WB, Trotta RF, Rector JT et al. Mechanisms for linezolidinduced anemia and thrombocytopenia. Ann Pharmacother 2003; 37: 517-20.
23. Falagas ME, Siempos II, Papagelopoulos PJ et al. Linezolid for the treatment of adults with bone and joint infections. Int J Antimicrob Agents 2007; 29: 233-9.
24. Garazzino S, De Rosa FG, Bargiacchi O et al. Haematological safety of long-term therapy with linezolid. Int J Antimicrob Agents 2007; 29: 480-3.
25. Gerson SL, Kaplan SL, Bruss JB et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother 2002; 46: 2723-6.
26. Kuter DJ, Tillotson GS. Hematologic effects of antimicrobials: focus on the oxazolidinone linezolid. Pharmacotherapy 2001; 21: 1010-3.
27. Lin YH, Wu VC, Tsai IJ et al. High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency. Int J Antimicrob Agents 2006; 28: 345-51.
28. Rouse MS, Piper KE, Jacobson M et al. Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis. J Antimicrob Chemother 2006; 57: 301-5.
29. Senneville E, Legout L, Valette M et al. Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case-control study. J Antimicrob Chemother 2004; 54: 798-802.
30. Bohlius J, Weingart O, Trelle S et al. Cancer-related anemia and recombinant human erythropoietin-an updated overview. Nat Clin Pract Oncol 2006; 3: 152-64.
31. Bernard L, Stern R, Lew D et al. Serotonin syndrome after concomitant treatment with linezolid and citalopram. Clin Infect Dis 2003; 36: 1197.
32. Bressler AM, Zimmer SM, Gilmore JL et al. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect Dis 2004; 4: 528-31.
33. De Vriese AS, Coster RV, Smet J et al. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis 2006; 42: 1111-7.
34. Lee E, Burger S, Shah J et al. Linezolid-associated toxic optic neuropathy: a report of 2 cases. Clin Infect Dis 2003; 37: 1389-91.
35. Legout L, Senneville E, Gomel JJ et al. Linezolid-induced neuropathy. Clin Infect Dis 2004; 38: 767-8.
36. Taylor JJ, Wilson JW, Estes LL. Linezolid and serotonergic drug interactions: a retrospective survey. Clin Infect Dis 2006; 43: 180-7.
37. Gander S, Hayward K, Finch R. An investigation of the antimicrobial effects of linezolid on bacterial biofilms utilizing an in vitro pharmacokinetic model. J Antimicrob Chemother2002; 49:301-8.
38. Jacqueline C, Caillon J, Le Mabecque V et al. In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods. J Antimicrob Chemother 2003; 51: 857-64.
39. Kim KA, Park PW, Liu KH et al. Effect of rifampin, an inducer of CYP3A and P-glycoprotein, on the pharmacokinetics of risperidone. J Clin Pharmacol 2008; 48: 66-72.
40. Weiner M, Burman W, Luo CC et al. Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. Antimicrob Agents Chemother 2007; 51: 2861-6.
41. Sakaeda T. MDR1 genotype-related pharmacokinetics: fact or fiction? Drug Metab Pharmacokinet 2005; 20: 391-414.
42. Chowbay B, Li H, David M et al. Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. Br J Clin Pharmacol 2005; 60: 159-71.
43. Gebhart BC, Barker BC, Markewitz BA. Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin. Pharmacotherapy 2007; 27: 476-9.
44. Zimmerli W, Widmer AF, Blatter M et al. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 1998; 279: 1537-41.
45. Soriano A, Ortega M, Garcia S et al. Comparative study of the effects of pyridoxine, rifampin, and renal function on hematological adverse 2230 events induced by linezolid. Antimicrob Agents Chemother 2007; 51: 2559-63.
46. Plachouras D, Giannitsioti E, Athanassia S et al. No effect of pyridoxine on the incidence of myelosuppression during prolonged linezolid treatment. Clin Infect Dis 2006; 43: e89-91.
47. Garrabou G, Soriano A, Lopez S et al. Reversible inhibition of mitochondrial protein synthesis during linezolid-related hyperlactatemia. Antimicrob Agents Chemother 2007; 51: 962-7.
48. Palenzuela L, Hahn NM, Nelson RP Jr et al. Does linezolid cause lactic acidosis by inhibiting mitochondrial protein synthesis? Clin Infect Dis 2005; 40: e113-6.
49. Egle H, Trittler R, Kummerer K et al. Linezolid and rifampin: drug interaction contrary to expectations? Clin Pharmacol Ther 2005; 77: 451-3.